1. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Issue 5 (May 2020) Authors: Pfisterer, Jacobus; Shannon, Catherine M; Baumann, Klaus; Rau, Joern; Harter, Philipp; Joly, Florence; Sehouli, Jalid; Canzler, Ulrich; Schmalfeldt, Barbara; Dean, Andrew P; Hein, Alexander; Zeimet, Alain G; Hanker, Lars C; Petit, Thierry; Marmé, Frederik; El-Balat, Ahmed; Glasspool, Rosalind; de... Journal: Lancet oncology Issue: Volume 21:Issue 5(2020) Page Start: 699 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine: Results of a prospective multi-center study at certified breast centers. (October 2016) Authors: Jacobs, Volker R.; Augustin, Doris; Wischnik, Arthur; Kiechle, Marion; Hoess, Cornelia; Steinkohl, Oliver; Rack, Brigitte; Kapitza, Thomas; Krase, Peter Journal: Breast Issue: Volume 29(2016) Page Start: 208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized ADEBAR trial. (June 2016) Authors: Schwentner, Lukas; Harbeck, Nadia; Singer, Susanne; Eichler, Martin; Rack, Brigitte; Forstbauer, Helmut; Wischnik, Arthur; Scholz, Christoph; Huober, Jens; Friedl, Thomas W.P.; Weissenbacher, Tobias; Härtl, Kristin; Kiechle, Marion; Janni, Wolfgang; Fink, Visnja Journal: Breast Issue: Volume 27(2016) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany. (18th September 2017) Authors: Dall, Peter; Koch, Thorsten; Göhler, Thomas; Selbach, Johannes; Ammon, Andreas; Eggert, Jochen; Gazawi, Nidal; Rezek, Daniela; Wischnik, Arthur; Hielscher, Carsten; Keitel, Stella; Cirrincione, Ursula; Hinke, Axel; Feisel‐Schwickardi, Gabriele Journal: Oncologist Issue: Volume 22:Number 2(2017) Page Start: 131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany. (February 2017) Authors: Dall, Peter; Koch, Thorsten; Göhler, Thomas; Selbach, Johannes; Ammon, Andreas; Eggert, Jochen; Gazawi, Nidal; Rezek, Daniela; Wischnik, Arthur; Hielscher, Carsten; Keitel, Stella; Cirrincione, Ursula; Hinke, Axel; Feisel‐Schwickardi, Gabriele Journal: Oncologist Issue: Volume 22:Number 2(2017) Page Start: 131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗